Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

China Structural Heart Devices Market

ID: MRFR/HC/55143-HCR
200 Pages
Rahul Gotadki
March 2026

China Structural Heart Devices Market Research Report By Type (Heart Valve Devices, Annuloplasty Rings, Occluders, Delivery Systems), By Indication (Valvular Heart Disease, Cardiomyopathy) and By Procedure (Replacement Procedures, Repair Procedures) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

China Structural Heart Devices Market Infographic
Purchase Options

China Structural Heart Devices Market Summary

As per Market Research Future analysis, the China Structural Heart Devices Market size was estimated at 57.75 USD Million in 2024. The Structural Heart-devices market is projected to grow from 61.61 USD Million in 2025 to 117.66 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 6.6% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The China structural heart-devices market is poised for substantial growth driven by technological advancements and an aging population.

  • Technological advancements in structural heart devices are enhancing treatment outcomes and patient safety.
  • The regulatory support from the government is fostering innovation and market entry for new devices.
  • The aging population in China is contributing to an increased demand for cardiovascular interventions.
  • Rising incidence of cardiovascular diseases and growing healthcare expenditure are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size 57.75 (USD Million)
2035 Market Size 117.66 (USD Million)
CAGR (2025 - 2035) 6.68%

Major Players

Edwards Lifesciences (US), Medtronic (US), Abbott Laboratories (US), Boston Scientific (US), LivaNova (GB), Terumo Corporation (JP), Cardinal Health (US), AtriCure (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

China Structural Heart Devices Market Trends

The China Structural Heart Devices Market is experiencing notable growth, driven by advancements in technology and an increasing prevalence of heart diseases. In recent years, there has been a marked rise in the adoption of minimally invasive procedures, which are preferred by both patients and healthcare providers. This shift is largely attributed to the benefits of reduced recovery times and lower risks associated with traditional surgical methods. Furthermore, the aging population in China is contributing to a higher demand for innovative solutions in cardiac care, as older individuals are more susceptible to heart-related conditions. As a result, manufacturers are focusing on developing cutting-edge devices that cater to the specific needs of this demographic. In addition to technological advancements, regulatory support plays a crucial role in shaping the structural heart-devices market. The Chinese government has implemented various policies aimed at enhancing healthcare infrastructure and promoting research and development in the medical device sector. This supportive environment encourages both domestic and international companies to invest in the market, leading to a wider array of products available to healthcare providers. Moreover, collaborations between industry stakeholders and research institutions are fostering innovation, which is likely to further propel the market forward. Overall, the structural heart-devices market appears poised for continued expansion, driven by a combination of technological innovation and supportive regulatory frameworks.

Technological Advancements

The structural heart-devices market is witnessing rapid technological advancements, particularly in the development of minimally invasive devices. These innovations are enhancing procedural efficiency and patient outcomes, making them increasingly attractive to healthcare providers.

Regulatory Support

Regulatory frameworks in China are evolving to support the growth of the structural heart-devices market. Government initiatives aimed at improving healthcare access and promoting medical device innovation are likely to stimulate market expansion.

Aging Population

The demographic shift towards an aging population in China is driving demand for structural heart devices. As older individuals are more prone to heart diseases, the need for effective treatment options is becoming increasingly critical.

China Structural Heart Devices Market Drivers

Government Initiatives and Funding

Government initiatives aimed at improving healthcare infrastructure and access to advanced medical technologies are pivotal for the structural heart-devices market. The Chinese government has been actively investing in healthcare reforms, which include increasing funding for cardiovascular health programs. These initiatives are designed to enhance the availability of structural heart devices in hospitals and clinics across the country. In recent years, the government has allocated significant resources to support research and development in the medical device sector, which is expected to bolster the market. By 2025, it is anticipated that government funding will contribute to a 15% increase in the adoption of structural heart devices, thereby expanding the market's reach and accessibility.

Increase in Healthcare Expenditure

The rise in healthcare expenditure in China is a significant driver for the structural heart-devices market. As the country continues to develop economically, there is a corresponding increase in spending on healthcare services and technologies. In 2025, healthcare expenditure is projected to reach approximately 7% of GDP, reflecting a growing commitment to improving health outcomes. This increase in funding allows for greater investment in advanced medical technologies, including structural heart devices. Hospitals and healthcare facilities are likely to allocate more resources towards acquiring these devices, thereby enhancing their treatment capabilities. Consequently, the structural heart-devices market is expected to experience robust growth as healthcare providers strive to meet the rising demand for effective cardiovascular treatments.

Growing Awareness and Patient Education

The rising awareness of heart health and the importance of early intervention is driving the structural heart-devices market in China. Educational campaigns and community outreach programs have been instrumental in informing the public about cardiovascular diseases and available treatment options. As patients become more informed, they are more likely to seek medical advice and treatment, leading to increased demand for structural heart devices. This trend is further supported by healthcare providers who are emphasizing the importance of preventive care and timely interventions. The structural heart-devices market is expected to benefit from this heightened awareness, as more patients opt for advanced treatment solutions to manage their heart conditions effectively.

Rising Incidence of Cardiovascular Diseases

The increasing prevalence of cardiovascular diseases in China is a primary driver for the structural heart-devices market. According to recent health statistics, cardiovascular diseases account for approximately 40% of all deaths in the country. This alarming trend necessitates advanced medical interventions, including structural heart devices, to manage and treat these conditions effectively. The demand for innovative solutions is further fueled by the growing awareness of heart health among the population. As healthcare providers seek to improve patient outcomes, investments in structural heart devices are likely to rise, indicating a robust growth trajectory for the market. Furthermore, the Chinese government has been promoting initiatives aimed at reducing the burden of cardiovascular diseases, which may lead to increased funding and support for the development and distribution of these devices.

Technological Innovations in Medical Devices

Technological advancements in medical devices are significantly influencing the structural heart-devices market. Innovations such as minimally invasive procedures, advanced imaging techniques, and improved materials are enhancing the efficacy and safety of heart devices. For instance, the introduction of transcatheter aortic valve replacement (TAVR) has revolutionized treatment options for patients with aortic stenosis. The market is projected to grow as manufacturers invest in research and development to create next-generation devices that offer better performance and patient outcomes. In 2025, the market for structural heart devices in China is expected to reach approximately $2 billion, driven by these technological innovations. As healthcare professionals increasingly adopt these advanced solutions, the structural heart-devices market is poised for substantial growth.

Market Segment Insights

By Type: Transcatheter Aortic Valve Replacement (Largest) vs. Mitral Valve Repair Devices (Fastest-Growing)

In the China structural heart-devices market, Transcatheter Aortic Valve Replacement (TAVR) currently holds the largest market share, driven by its high adoption rates and effectiveness in treating severe aortic stenosis. Mitral Valve Repair Devices, while trailing in overall market share, have shown significant interest and investment, indicating a vibrant growth potential within this segment. The growth trends in the China structural heart-devices market are largely propelled by an aging population, increasing prevalence of cardiovascular diseases, and advancements in technology. Mitral Valve Repair Devices are emerging rapidly due to the growing recognition of less invasive treatment options, while TAVR continues to dominate due to its established efficacy and procedural benefits, positioning it well against the backdrop of evolving regulatory landscapes.

Transcatheter Aortic Valve Replacement (Dominant) vs. Mitral Valve Repair Devices (Emerging)

Transcatheter Aortic Valve Replacement (TAVR) is characterized by its minimally invasive procedure that offers significant benefits for patients with aortic valve stenosis, leading to its dominant position in the market. This segment has benefitted from technological advancements and strong clinical support. On the other hand, Mitral Valve Repair Devices are considered an emerging technology, gaining traction as more healthcare providers seek alternatives to traditional surgical methods. They are particularly appealing due to reduced recovery times and better patient outcomes. As healthcare focus shifts toward personalized and less invasive solutions, both segments are expected to witness dynamic growth, with TAVR maintaining its lead and Mitral Valve Repair Devices rapidly catching up.

By Procedure Type: Minimally Invasive (Largest) vs. Surgical (Fastest-Growing)

In the China structural heart-devices market, the procedure type segmentation showcases a compelling distribution of market share among Minimally Invasive, Surgical, and Percutaneous techniques. Currently, Minimally Invasive stands as the largest segment, driven by the growing preference for effective yet less invasive treatment options. Surgical methods, while historically prominent, are increasingly challenged by advancements in percutaneous technologies, shifting the competitive landscape. Growth trends indicate that the Surgical segment is emerging as the fastest-growing category, attributable to technological innovations and increasing acceptance of hybrid surgical techniques. Factors such as an aging population and rising cardiovascular diseases further drive the demand for both minimally invasive and surgical solutions. The overall trend leans towards integrating innovative techniques that combine the benefits of both segments, enhancing patient outcomes and adoption rates.

Minimally Invasive (Dominant) vs. Surgical (Emerging)

The Minimally Invasive segment represents a dominant force in the China structural heart-devices market, characterized by its emphasis on reduced recovery times and lower complications. This approach aligns with patient preferences for procedures that minimize trauma while ensuring effective treatment for structural heart conditions. Innovations in device design and surgical techniques have significantly contributed to this segment's appeal. Conversely, the Surgical segment is emerging as a vital player due to ongoing advancements and increased procedural efficiencies. Surgical methods are becoming more integrated with minimally invasive practices, allowing for a blend of both methods to address complex heart conditions. As surgical approaches evolve, they cater to a broader range of patients, enhancing surgical outcomes and driving growth.

By Indication: Aortic Stenosis (Largest) vs. Mitral Regurgitation (Fastest-Growing)

In the China structural heart-devices market, the indication segment reveals that Aortic Stenosis holds the largest market share, significantly outpacing other indications. Mitral Regurgitation and Heart Failure follow, with Mitral Regurgitation being recognized for its impressive growth rate, fueled by advancing technologies and increasing patient awareness. Growth trends within this segment are largely driven by the rising prevalence of cardiovascular diseases and an aging population. Additionally, innovations in device technology and improved procedural outcomes have contributed to the expanding market for Mitral Regurgitation treatments. As awareness of heart-related issues grows, both segments are set to carve out larger portions of the market in the coming years, supported by healthcare initiatives and enhanced access to care.

Aortic Stenosis (Dominant) vs. Mitral Regurgitation (Emerging)

Aortic Stenosis remains the dominant indication within the China structural heart-devices market, characterized by its robust demand for transcatheter aortic valve replacement (TAVR) procedures. This segment sees extensive support from established clinical practices and a solid base of healthcare providers trained in managing the condition. Conversely, Mitral Regurgitation is an emerging segment gaining traction, driven by innovative solutions such as percutaneous mitral valve repair techniques, which are rapidly gaining acceptance. While Aortic Stenosis benefits from a well-entrenched position, Mitral Regurgitation offers significant growth potential as it addresses a broader range of patient needs and paves the way for more treatment options.

By End User: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

In the China structural heart-devices market, hospitals represent the largest segment, capturing a significant share due to their comprehensive services and advanced infrastructure. Ambulatory surgical centers, while smaller in share, are rapidly gaining traction as more patients prefer outpatient procedures that minimize hospital stays. Cardiology clinics, although vital, currently hold a smaller market share, focusing primarily on specialized treatments and follow-up care for patients with cardiovascular conditions. The growth trends indicate a robust expansion in ambulatory surgical centers driven by the increasing preference for minimally invasive procedures and shorter recovery times, appealing to both patients and healthcare providers. Hospitals are expected to maintain their dominance, but the growth of specialized cardiology clinics is noteworthy as they adapt to evolving healthcare needs, emphasizing patient-centric models and collaborative approaches to heart care.

Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging)

Hospitals dominate the market due to their capacity to provide a wide range of healthcare services, equipped with advanced technology and expert personnel specializing in structural heart procedures. The expansive networks of hospitals allow them to handle complex cases, making them the preferred destination for critical care. In contrast, ambulatory surgical centers are emerging rapidly, driven by patient demand for cost-effective and efficient care. These centers focus on outpatient surgical procedures and have significantly lower operational costs, which translates into savings for patients. Their growth reflects a shift towards more accessible healthcare options, enhancing patient satisfaction through quicker recovery times and personalized care.

Get more detailed insights about China Structural Heart Devices Market

Key Players and Competitive Insights

The structural heart-devices market is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of cardiovascular diseases. Key players such as Edwards Lifesciences (US), Medtronic (US), and Abbott Laboratories (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Edwards Lifesciences (US) focuses on innovation, particularly in transcatheter heart valves, while Medtronic (US) emphasizes a broad portfolio that includes both surgical and minimally invasive solutions. Abbott Laboratories (US) is leveraging its strong R&D capabilities to introduce novel devices, thereby positioning itself as a leader in the market. Collectively, these strategies foster a competitive environment that is increasingly centered on innovation and technological differentiation.In terms of business tactics, companies are localizing manufacturing to reduce costs and enhance supply chain efficiency. This approach is particularly relevant in China, where regulatory frameworks and market demands necessitate a tailored approach. The market structure appears moderately fragmented, with several players vying for market share, yet dominated by a few key companies that exert considerable influence over pricing and product development. The collective actions of these major players shape the competitive dynamics, as they strive to capture a larger share of the growing market.

In October Medtronic (US) announced the launch of its latest transcatheter aortic valve replacement (TAVR) device, which is designed to improve patient outcomes through enhanced delivery systems. This strategic move underscores Medtronic's commitment to innovation and its focus on addressing the needs of patients with aortic stenosis. The introduction of this device is likely to strengthen Medtronic's position in the market, as it aligns with the increasing demand for less invasive treatment options.

In September Abbott Laboratories (US) expanded its partnership with a leading Chinese hospital network to enhance clinical trials for its heart valve products. This collaboration is significant as it not only accelerates the development of new technologies but also facilitates Abbott's entry into the rapidly growing Chinese market. By aligning with local healthcare providers, Abbott is poised to gain valuable insights into patient needs and preferences, which could inform future product development.

In November Edwards Lifesciences (US) announced a strategic investment in a local Chinese startup focused on artificial intelligence (AI) applications in cardiac care. This investment reflects a broader trend towards digitalization within the industry, as companies seek to integrate AI to improve diagnostic accuracy and patient management. Such initiatives are likely to enhance Edwards Lifesciences' competitive edge by positioning it at the intersection of technology and healthcare.

As of November the competitive landscape is increasingly defined by trends such as digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and expanding market reach. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition towards a focus on technological innovation, reliability in supply chains, and enhanced patient outcomes. This transition may redefine how companies position themselves in the market, emphasizing the importance of adaptability and forward-thinking strategies.

Key Companies in the China Structural Heart Devices Market include

Industry Developments

The China Structural Heart Devices Market has witnessed significant developments and current affairs recently. In October 2023, Medtronic announced the expansion of its market offerings, focusing on innovative technologies for structural heart interventions in China. Boston Scientific has been enhancing its presence with new product approvals, catering to the growing demand for minimally invasive treatments. 

Additionally, Terumo has been actively working on collaborations with local hospitals to advance research and development initiatives in the Chinese market. Notably, in August 2023, Edwards Lifesciences launched a new heart valve product tailored for Chinese patients, addressing the specific needs of the population. Regarding mergers and acquisitions, Neovasc has been in discussions for strategic partnerships aimed at expanding its reach in the region, reflecting the ongoing trend of consolidation in this market space. 

Throughout 2022, the emphasis on cardiac rhythm management technologies has grown, driven by increasing cardiovascular diseases in China, which has significantly affected market valuations and investment strategies amongst players like Abbott and LivaNova. The robust growth trajectory of this market is also supported by favorable government policies encouraging medical innovations and improved healthcare access.

 

Future Outlook

China Structural Heart Devices Market Future Outlook

The Structural Heart Devices Market in China is projected to grow at a 6.68% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of heart diseases, and rising healthcare expenditure.

New opportunities lie in:

  • Development of minimally invasive surgical techniques for heart valve repair.
  • Expansion of telehealth services for remote patient monitoring and follow-up.
  • Investment in R&D for innovative biomaterials in device manufacturing.

By 2035, the structural heart-devices market is expected to achieve substantial growth and innovation.

Market Segmentation

China Structural Heart Devices Market Type Outlook

  • Transcatheter Aortic Valve Replacement
  • Mitral Valve Repair Devices
  • Left Atrial Appendage Closure Devices
  • Transcatheter Pulmonary Valve

China Structural Heart Devices Market End User Outlook

  • Hospitals
  • Ambulatory Surgical Centers
  • Cardiology Clinics

China Structural Heart Devices Market Indication Outlook

  • Aortic Stenosis
  • Mitral Regurgitation
  • Heart Failure
  • Pulmonary Valve Stenosis

China Structural Heart Devices Market Procedure Type Outlook

  • Minimally Invasive
  • Surgical
  • Percutaneous

Report Scope

MARKET SIZE 2024 57.75(USD Million)
MARKET SIZE 2025 61.61(USD Million)
MARKET SIZE 2035 117.66(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.68% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Edwards Lifesciences (US), Medtronic (US), Abbott Laboratories (US), Boston Scientific (US), LivaNova (GB), Terumo Corporation (JP), Cardinal Health (US), AtriCure (US)
Segments Covered Type, Procedure Type, Indication, End User
Key Market Opportunities Advancements in minimally invasive procedures enhance growth potential in the structural heart-devices market.
Key Market Dynamics Rising demand for minimally invasive procedures drives innovation in structural heart-devices within the competitive landscape.
Countries Covered China
Author
Author
Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Leave a Comment

FAQs

What is the current valuation of the China structural heart-devices market?

<p>The market valuation was $57.75 Million in 2024.</p>

What is the projected market size for the China structural heart-devices market by 2035?

<p>The market is projected to reach $117.66 Million by 2035.</p>

What is the expected CAGR for the China structural heart-devices market during the forecast period 2025 - 2035?

<p>The expected CAGR is 6.68% during the forecast period.</p>

Which companies are the key players in the China structural heart-devices market?

<p>Key players include Edwards Lifesciences, Medtronic, Abbott Laboratories, Boston Scientific, LivaNova, Terumo Corporation, Cardinal Health, and AtriCure.</p>

What are the main segments of the China structural heart-devices market?

<p>The main segments include Type, Procedure Type, Indication, and End User.</p>

What was the valuation of Transcatheter Aortic Valve Replacement in 2024?

<p>The valuation for Transcatheter Aortic Valve Replacement was between $20.0 Million and $40.0 Million.</p>

How much is the Mitral Valve Repair Devices segment valued at in 2024?

<p>The Mitral Valve Repair Devices segment was valued between $15.0 Million and $30.0 Million.</p>

What is the projected valuation for the Left Atrial Appendage Closure Devices segment by 2035?

<p>The Left Atrial Appendage Closure Devices segment is expected to grow to between $10.0 Million and $20.0 Million by 2035.</p>

Which end user segment had the highest valuation in 2024?

<p>The Hospitals segment had the highest valuation, ranging from $30.0 Million to $60.0 Million.</p>

What is the projected growth for the Pulmonary Valve Stenosis indication by 2035?

<p>The Pulmonary Valve Stenosis indication is projected to grow to between $10.75 Million and $22.66 Million by 2035.</p>

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions